0001415889-24-001831.txt : 20240125 0001415889-24-001831.hdr.sgml : 20240125 20240125200034 ACCESSION NUMBER: 0001415889-24-001831 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240123 FILED AS OF DATE: 20240125 DATE AS OF CHANGE: 20240125 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MIDDLETON FRED A CENTRAL INDEX KEY: 0001267959 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39538 FILM NUMBER: 24563796 MAIL ADDRESS: STREET 1: 400 SOUTH EL CAMINO REAL STE 1200 CITY: SAN MATEO STATE: CA ZIP: 94402-1708 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CalciMedica, Inc. CENTRAL INDEX KEY: 0001534133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 452120079 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 BUSINESS PHONE: 858-952-5500 MAIL ADDRESS: STREET 1: 505 COAST BOULEVARD SOUTH STREET 2: SUITE 307 CITY: LA JOLLA STATE: CA ZIP: 92037 FORMER COMPANY: FORMER CONFORMED NAME: CalciMedica, Inc. /DE/ DATE OF NAME CHANGE: 20230322 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG VISION, INC. DATE OF NAME CHANGE: 20170717 FORMER COMPANY: FORMER CONFORMED NAME: GRAYBUG, Inc. DATE OF NAME CHANGE: 20150303 4 1 form4-01252024_080106.xml X0508 4 2024-01-23 0001534133 CalciMedica, Inc. CALC 0001267959 MIDDLETON FRED A C/O CALCIMEDICA, INC. 505 COAST BLVD. S. #307 LA JOLLA CA 92037 true false true false 0 Common Stock 2024-01-23 4 P 0 243356 3.702 A 946744 I By Sanderling Venture Partners VI, LP Common Stock 2024-01-23 4 P 0 144676 3.702 A 727433 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Common Stock 2024-01-23 4 P 0 194472 3.702 A 435148 I By Sanderling Ventures VII, L.P. Common Stock 2024-01-23 4 P 0 51032 3.702 A 114260 I By Sanderling Ventures VII (Canada), L.P. Common Stock 2024-01-23 4 P 0 13184 3.702 A 27609 I By Sanderling Ventures VII Annex Fund, L.P. Common Stock 2024-01-23 4 P 0 3920 3.702 A 21602 I By Sanderling Ventures Management VI Common Stock 2024-01-23 4 P 0 28744 3.702 A 30292 I By Sanderling Ventures Management VII Common Stock 11714 D Common Stock 8176 I By Golden Triangle Ventures, LLC Warrant 5.36 2024-01-23 4 P 0 121678 0.125 A 2024-01-23 2024-12-31 Common Stock 121678 121678 I By Sanderling Venture Partners VI, LP Warrant 7.15 2024-01-23 4 P 0 121678 0.125 A 2024-01-23 2026-12-31 Common Stock 121678 121678 I By Sanderling Venture Partners VI, LP Warrant 5.36 2024-01-23 4 P 0 72338 0.125 A 2024-01-23 2024-12-31 Common Stock 72338 72338 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Warrant 7.15 2024-01-23 4 P 0 72338 0.125 A 2024-01-23 2026-12-31 Common Stock 72338 72338 I By Sanderling Venture Partners VI Co-Investment Fund, L.P. Warrant 5.36 2024-01-23 4 P 0 97236 0.125 A 2024-01-23 2024-12-31 Common Stock 97236 97236 I By Sanderling Ventures VII, L.P. Warrant 7.15 2024-01-23 4 P 0 97236 0.125 A 2024-01-23 2026-12-31 Common Stock 97236 97236 I By Sanderling Ventures VII, L.P. Warrant 5.36 2024-01-23 4 P 0 25516 0.125 A 2024-01-23 2024-12-31 Common Stock 25516 25516 I By Sanderling Ventures VII (Canada), L.P. Warrant 7.15 2024-01-23 4 P 0 25516 0.125 A 2024-01-23 2026-12-31 Common Stock 25516 25516 I By Sanderling Ventures VII (Canada), L.P. Warrant 5.36 2024-01-23 4 P 0 6592 0.125 A 2024-01-23 2024-12-31 Common Stock 6592 6592 I By Sanderling Ventures VII Annex Fund, L.P. Warrant 7.15 2024-01-23 4 P 0 6592 0.125 A 2024-01-23 2026-12-31 Common Stock 6592 6592 I By Sanderling Ventures VII Annex Fund, L.P. Warrant 5.36 2024-01-23 4 P 0 1960 0.125 A 2024-01-23 2024-12-31 Common Stock 1960 1960 I By Sanderling Ventures Management VI Warrant 7.15 2024-01-23 4 P 0 1960 0.125 A 2024-01-23 2026-12-31 Common Stock 1960 1960 I By Sanderling Ventures Management VI Warrant 5.36 2024-01-23 4 P 0 14372 0.125 A 2024-01-23 2024-12-31 Common Stock 14372 14372 I By Sanderling Ventures Management VII Warrant 7.15 2024-01-23 4 P 0 14372 0.125 A 2024-01-23 2026-12-31 Common Stock 14372 14372 I By Sanderling Ventures Management VII The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Venture Partners VI, LP ("SVP VI, LP", together with Sanderling Venture Partners VI Co-Investment Fund, L.P., Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling Ventures Management VI and Sanderling VI Limited Partnership (the "Sanderling VI Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VI Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the securities of the Issuer held by Sanderling Ventures VII, LP ("SVP VII, LP", together with Sanderling Ventures Management VII, Sanderling Ventures VII (Canada), L.P. and Sanderling Ventures VII Annex Fund, L.P., the "Sanderling VII Shares"). The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The Reporting Person, a director of Sanderling Ventures, may be deemed to beneficially own the Sanderling VII Securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The Reporting Person is a managing member of Golden Triangle Ventures LLC and may be deemed to beneficially own the securities of the Issuer held by Golden Triangle Ventures LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter. The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter. /s/ John Dunn, Attorney-in-Fact 2024-01-25